Standard treatment for advanced endometrial cancer may soon change. A study found that people with advanced or recurrent endometrial cancer who received immunotherapy with chemotherapy had better outcomes than those who had chemotherapy alone.
https://www.facingourrisk.org/XRAY/immunotherapy-improves-advanced-endometrial-cancer-outcomes
In patients with advanced or recurrent endometrial cancer, the addition of pembrolizumab to standard chemotherapy resulted in significantly longer progression-free survival than with chemotherapy alone.
Uptake of RRS before 50 years of age was low, and RRS was rarely undertaken in association with surgical treatment of CRC.
Uptake of RRS aligned poorly with gene- and age-associated risk estimates for endometrial or ovarian cancer that were published recently from PLSD and did not correspond well with current clinical guidelines.
The reasons should be clarified. Decision-making on opting for or against RRS and its timing should be better aligned with predicted risk and mortality for endometrial and ovarian cancer in Lynch syndrome to improve outcomes.
Lynch syndrome (LS) markedly increases risks of colorectal and endometrial cancers. Early detection biomarkers for LS cancers could reduce the needs for invasive screening and surgical prophylaxis.
Prevention Relevance:
Methylated DNA markers previously identified in sporadic endometrial cancer and colorectal cancer discriminate between benign and cancer tissue in LS.
“In navigating the effects of accelerated aging post-oophorectomy, HRT can be an essential tool for those who have not achieved menopause. While it can alleviate various symptoms and health risks, it is crucial to discuss its potential benefits and drawbacks with a healthcare provider.”
Phase 1 was launched on September 20th 2021. It is a personalised
online resource for women impacted by cervical cancer. If you have a partner in your life, this platform can also support them. If you are a health care provider working in the area this can also support you and your
practice.
If you are newly diagnosed, receiving treatment, in surveillance
or living well with and beyond cancer thisisGO.ie has information that is
tailored to meet your needs.
During 2022 the remaining 4 gynaecological cancers Ovarian, Uterine, Vulval and Vaginal were launched as well as the addition of a genetic pathway for those impacted by BRCA and Lynch Syndrome.
– Adenomatous Polyposis Testing Criteria
– Attenuated Familial Adenomatous Polyposis
– Colonic Adenomatous Polyposis of Unknown Etiology
– Familial Adenomatous Polyposis
– Juvenile Polyposis Syndrome
– Lynch Syndrome
– MUTYH-Associated Polyposis
– Peutz-Jeghers Syndrome
– Serrated Polyposis Syndrome
Lynch Syndrome is an inherited condition that increases your risk of developing some cancers, including bowel, womb and ovarian cancer. This is a guide to run through everything you need to know about Lynch.
This guide has been made with input from experts, people with Lynch Syndrome and Ask Eve nurses to provide you with all the information you need when offered testing for, or navigating a diagnosis of, Lynch Syndrome.
We also have an Easy Read guide to Lynch Syndrome, which you can download here
Lynch Syndrome Ireland 